Transcatheter Tricuspid Valve Intervention (TTVI) Market Size, Share, Industry, Forecast and outlook (2024-2031)

Transcatheter Tricuspid Valve Intervention (TTVI) Market is Segmented By Intervention Type (Tricuspid Valve Repair (TVr), Tricuspid Valve Replacement (TVR)), By Disease Type (Tricuspid Stenosis (TS), Tricuspid Regurgitation (TR)), By End-User (Ambulatory Surgical Centers, Hospitals, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Transcatheter Tricuspid Valve Intervention Market Size

Transcatheter tricuspid valve intervention (TTVI) market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a high CAGR during the forecast period (2023-2030).

Tricuspid valve regurgitation is a type of heart valve disease in which the valve between the two right heart chambers (right ventricle and right atrium) doesn't close properly. As a result, blood leaks backward into the upper right chamber (right atrium). Patients with chronic TR have traditionally been treated medically, which has resulted in annular dilatation and end-stage right ventricular (RV) heart failure. Transcatheter tricuspid valve intervention (TTVI) has recently emerged as an alternative for treating severe tricuspid regurgitation (TR).

Transcatheter Tricuspid Valve Intervention Market Scope

For More insights about the Market Request Free Sample

Transcatheter Tricuspid Valve Intervention Market Trends

Novel Techniques developed for treating tricuspid regurgitation (TR) are expected to drive market growth.

Tricuspid regurgitation (TR) negatively influences both quality of life and long-term survival, sparking interest in treatment ways to counteract these effects. Historically, the only treatment option for TR was surgery, which is often accompanied by considerable morbidity and mortality in older patients with other comorbidities. Due to a lack of therapeutic choices, transcatheter tricuspid valve intervention (TTVI) has rapidly evolved. A wide range of techniques is studied, and early data suggests that TTVI improves clinical outcomes. Today, TTVI is based on various methods, including edge-to-edge repair, annular reduction, spacers, caval valve implantation, and transcatheter tricuspid valve replacement. For instance, Many TR diseases involve annular dilatation, and many surgical methods, particularly in the early phases of TR, focus on annuloplasty as a primary technique. Percutaneous annular reduction techniques, on the other hand, aim to emulate surgical annuloplasty by shrinking the tricuspid annulus, closing the coaptation gap, and restoring leaflet approximation. Thus, the market is expected to drive in the forecast period from the above statements.

Risks associated with the Transcatheter Tricuspid Valve Intervention (TTVI) surgery are expected to hamper the market growth.

The risks of tricuspid valve repair and replacement vary based on health, the treatment, and the healthcare team's skill. To lessen the risk of complications, tricuspid valve surgery should be performed at a medical center with skilled staff who have performed many tricuspid valve surgeries. Bleeding, blood clots, valve malfunction in replacement valves (valve prosthesis), heart rhythm disorders, infection, stroke, or even death are all risks connected with tricuspid valve repair and replacement operations.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The lockdown restrictions, as well as the pandemic itself, have caused extensive modifications in healthcare operations. Many countries and healthcare systems, particularly in critical care, have experienced substantial service strain. It has demanded the reorganization of resources to meet those needs. COVID-19 has altered how people connect with health services at the same time. There was a rapid and significant decrease in TAVR and SAVR activity during the COVID-19 pandemic. It is estimated that over the period March to June 2020, this decline in activity accounts for an estimated 2294 patients with severe aortic stenosis left untreated by TAVR or surgical intervention.

Moreover, because of lockdowns, travel boycotts, and other factors, the COVID-19 epidemic has affected clinical and confirmatory trials, pipeline milestones, and regulatory clearances and approvals of tricuspid valve repair and replacement devices in several countries. Thus, COVID-19 has profoundly impacted clinical and surgical practice at every level, with the suspension or postponement of screening, medical association approvals, and clinical trial activities.

Transcatheter Tricuspid Valve Intervention Market Segment Analysis

Tricuspid Valve Repair (TVr) segment is expected to hold the largest market share in transcatheter tricuspid valve intervention (TTVI) market

The tricuspid valve repair (TVr) segment is expected to dominate in 2020. Most tricuspid valve disorders are mechanical and cannot be successfully managed with medicine alone. Symptoms and the risk of consequences, such as heart failure, will eventually necessitate surgery. The decision to repair a damaged tricuspid valve depends on many things, including the severity of your tricuspid valve disease, age and overall health of the patient and others. Heart valve repair is usually the first choice because it's associated with a lower risk of infection. Valve repair preserves and improves heart function, and it may reduce the potential need for long-term use of blood-thinning medications. Thus, it has increased the demand for Tricuspid Valve Repair (TVr), due to which the market segment is expected to hold the largest market share in the forecast period.

Transcatheter Tricuspid Valve Intervention Market Geographical Share

North America region holds the largest market share in the global transcatheter tricuspid valve intervention (TTVI) market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of tricuspid valve diseases, increasing preference for transcatheter tricuspid valve intervention devices for treatment, and technological advancements lead to enhanced Transcatheter Tricuspid Valve Intervention applications, product launches by the market players, and easy availability of reimbursement are some factors that the market is expected to boost in the forecast period. For instance, The prevalence of TR is increasing, with an estimated prevalence of around 1.6 million patients with significant TR in the USA. Nonetheless, fewer than 8,000 patients undergo tricuspid valve surgery per year. Moreover, recent research further showed that the inclusion of TA at the time of mitral valve surgery resulted in a lower risk of a primary-end-point event at 2 years than those who underwent mitral-valve surgery alone.

Additionally, Abbott Laboratories of Abbott Park, Illinois, has acquired CE approval for its Triclip transcatheter tricuspid valve repair system. According to the manufacturer, the device is a non-surgical treatment for tricuspid regurgitation (TR), and it is the first commercially available minimally invasive clip-based tricuspid valve repair device. The Triclip is a device supplied to the heart through the femoral vein in the leg and reduces blood backflow by clipping together a part of the tricuspid valve's leaflets. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Transcatheter Tricuspid Valve Intervention Market Companies

Major key players in the transcatheter tricuspid valve intervention (TTVI) market are Edwards Lifesciences, Abbott Laboratories, Medtronic, Venus MedTech, Navigate Cardiac Structures, Inc., CroíValve         and Cardiovalve.    

Abbott Laboratories:

Overview:

Abbott Laboratories (Abbott) develops, manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.

­Product Portfolio:

TriClip Transcatheter Tricuspid Valve Repair: It offers a sustained reduction of TR with significant clinical outcomes and proven safety improvement. It is built upon a proven clip-based platform uniquely designed for the right heart.